From hypertension to diabetes, National Pharmaceutical Pricing Authority caps retail price of 39 medicines

The National Pharmaceutical Pricing Authority (NPPA) has capped the retail price of 39 medicines. The government’s regulatory agency has slashed prices for drugs, including those used in the treatment of hypertension, diabetes, and heart disease, among others.

National Pharmaceutical Pricing Authority (NPPA) has capped the retail price of 39 medicines, including those for hypertension, diabetes, heart disease, etc pic.twitter.com/jc4CVUIx8c

— CNBC-TV18 (@CNBCTV18Live) July 11, 2026

In the notification, the Ministry of Chemicals and Fertilisers said that the manufacturers of formulations or “new dry”, of the DPCO, 2013, shall fix the retail price not exceeding the price.

 

 

 

Furthermore, the statement said that any other existing manufacturer launching the same new drug within twelve months of the date of publication of this notification in the Official Gazette is permitted to do so at a retail price not exceeding the price specified in the column.

Some of the drugs mentioned in the list include Tenecteplase (TNK-TPA) Injection, Combikit Darunavir, Ritonavir & Dolutegravir Tablets, Amoxicillin, Aspirin and Potassium Clavulanate Dispersible Tablets, among others

Also Read: Retail prices capped for 42 medicines, including anti-diabetic drugs and antibiotic formulations

This decision comes about a couple of months after a similar move in which the NPPA reduced retail prices of 42 drug formulations. In this decision, taken in May by the National Pharmaceutical Pricing Authority (NPPA) under the Drugs Prices Control Order (DPCO), according to a notification issued by the Ministry of Chemicals and Fertilisers.